Compare Anheuser-Busch Inbev SA (BUD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Viatris Inc — how do they compare? Anheuser-Busch Inbev SA trades at $80.87 (market cap $159.01B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Anheuser-Busch Inbev SA is far larger — about 8.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BUD | VTRS | |
|---|---|---|
Market Cap | $159.01B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $17.86 |
52-Week Low | $57.93 | $9.49 |
Enterprise Value | $223.42B | $30.80B |
Dividend Yield | 1.67% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.20, down 4.69% today, with technical indicators showing bearish momentum. The stock shows solid fundamentals with 2025 revenue of $59.32B and net income margin improving to 11.52%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 estimate. Analyst consensus remains bullish with 57.8% buy ratings and $90.17 price target, representing 14% upside potential from current levels.
The outlook remains positive given strong cash flow generation and debt reduction trends, though near-term technical weakness and competitive pressures in the beer industry present risks. Institutional activity shows mixed signals with recent share sales by Cetera Investment Advisers offset by Bank of New York Mellon purchases.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
